Related Experiment Video
Updated: Jul 19, 2025

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
Published on: September 2, 2021
Clinical Applications for Gasotransmitters in the Cardiovascular System: Are We There Yet?
Elisa Arrigo1, Stefano Comità1, Pasquale Pagliaro1
1Department of Clinical and Biological Sciences, University of Torino, 10124 Turin, Italy.
Abstract:
Ischemia is the underlying mechanism in a wide variety of acute and persistent pathologies. As such, understanding the fine intracellular events occurring during (and after) the restriction of blood supply is pivotal to improving the outcomes in clinical settings. Among others, gaseous signaling molecules constitutively produced by mammalian cells (gasotransmitters) have been shown to be of potential interest for clinical treatment of ischemia/reperfusion injury. Nitric oxide (NO and its sibling, HNO), hydrogen sulfide (H2S), and carbon monoxide (CO) have long been proven to be cytoprotective in basic science experiments, and they are now awaiting confirmation with clinical trials. The aim of this work is to review the literature and the clinical trials database to address the state of development of potential therapeutic applications for NO, H2S, and CO and the clinical scenarios where they are more promising.
More Related Videos
Related Concept Videos
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Nitric Oxide Signaling Pathway
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Heart Failure Drugs: Inotropic Agents
Gas Exchange and Transport

